Objective: Bipolar disorder has a wide range of clinical manifestations which may progress over time. The aim of this study was to test the applicability of a clinical staging model for bipolar disorder and to gain insight into the nature of the variables influencing progression through consecutive stages.
| INTRODUC TI ON
Bipolar disorder (BD) has a wide range of clinical manifestations with depressive, hypomanic and manic episodes next to euthymic intervals. 1 Classification systems such as DSM-5 2 and ICD-10 3 have
led to a more unified definition of criteria for mood disorders. Still, considerable heterogeneity remains in the longitudinal course of BD, ranging from a single manic episode to frequent alternating mood episodes or even chronic illness.
Staging models have the potential to further classify psychiatric disorders in relationship to their differential long-term course.
Fava and Kellner 4 were the first to emphasize the importance of staging in psychiatry, which was then further promoted by
McGorry et al. 5 Based on McGorry's model for psychotic and severe mood disorders, Berk et al 6 proposed a staging model for bipolar disorders, largely defined by the occurrence and recurrence of mood episodes. In the staging model by Berk et al, stage 0 (at risk), stage 1 (prodromal), stage 2 (first episode), stage 3 (recurrent episodes), and stage 4 (chronic, unremitting illness) are distinguished. Kapczinski et al 7 proposed an alternative staging model, focusing on inter-episodic functional impairment and potential biomarkers. For this study, we decided to focus on the model by Berk et al 6 for which Kupka & Hillegers 8 proposed some modifications, defining initial depressive episodes without a history of (hypo)mania as a prodromal stage of bipolar disorder, as was also proposed by Duffy et al. 9 For the current study, we further refined this staging model (see Table 2 and Appendix 1).
Unlike other fields of medicine, staging models have not yet been widely implemented in psychiatry. First, the models' applicability must be assessed. 11 provided a unique opportunity to apply a staging model on patient data. The main objective of the current study was to assess the applicability of a clinical staging model for BD. The second aim was to gain insight in the natural progression through the stages of BD in the first 5 years after onset of BD (ie, entry of stage 2) and to investigate whether illness progression was influenced by items considered to be of clinical significance, eg age at onset, sex, monoor biphasic initial episode, or a first degree relative with BD.
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| Study sample
Participants of the Dutch site of the Stanley Foundation Bipolar
Network Naturalistic Follow-up Study (SFBN-NFS) of whom a comprehensive retrospective LifeChart (LCM-p) 13 was available (n = 99)
were included in the study. Subjects were recruited from psychiatric outpatient clinics between 1995 and 2001. In order to get a broad coverage of the bipolar spectrum, few restrictions were applied to subjects before entering the SFBN-NFS. Inclusion criteria were age over 18 years and diagnosis of BD I, II or Not Otherwise Specified according to the DSM-IV-confirmed by a clinical interview including SCID 14 at study entry. Only subjects with active substance abuse requiring additional treatment were excluded. The methodology of the SFBN-NFS was published elsewhere. 11 We received approval for SFBN-NFS from the IRB of the University Medical Center Utrecht, Netherlands, and all patients gave written informed consent (Table 1) .
Of each participant, a retrospective life chart (LCM-r) ranging from onset of first mood symptoms until study entry was reconstructed, according to the guidelines in the NIMH LCM-manual, 15 resulting in a graphic representation of the past longitudinal illness course, including initial prodromal symptoms. The severity rating of mood episodes was based on both the severity of manic and depressive symptoms and the degree of associated functional impairment. 16 Per these guidelines, all available information from clinical and personal records and repeated clinical interviews was collected by a trained research clinician. The occurrence and severity of mood episodes were determined for every consecutive month.
| Application of the clinical staging model
Using duplicates of the original hand-completed LCM-r graphics for all 99 subjects, three clinicians (AM, UK, RK) independently assigned the occurrence, duration and temporal sequence of stages for each month after initial symptoms, using the modified staging model by Berk et al 6, 8 (Table 2) , and further refined for application 
Conclusions:
Staging is a useful model to determine illness progression in longitudinal life chart data. Variables influencing transition rates were successfully identified.
K E Y W O R D S
biphasic onset, bipolar disorder, male sex, mood disorders, multi-state model, staging, staging models Since we used life charts covering the period from first symptoms until study entry (range 10 months to 45 years), the overall course of each mood episode was known at the time the stages were assigned. We decided to use a prospectively oriented reconstruction, ie if an episode would eventually last 2 years or more, stage 4 (chronic course) was only assigned after these 2 years, after first recording all applicable preceding stages. Functional recovery was defined as return of mood to baseline for at least 2 months.
Since our main interest covered illness progression during the first 5 years after the onset of BD, data were right-censored 60 months after onset of BD (stage 2) or earlier if the time between onset and inclusion was less than 60 months (N = 13), resulting in a maximum of 60 data-points per subject. The interrater reliability was calculated for the full stages, ie without subgroups.
| Statistical analyses
The data were prepared for statistical analysis by a multi-state model. As not all subjects experienced each subsequent stage, subjects could enter the study in a higher stage and/or skip stages. By definition, backward transition was only possible from stage 4 to 3.
We distinguished the transition from stage 2 to 3 as primary entry of stage 3 (3.1); conversion from stage 4 back to stage 3 was defined as secondary entry of stage 3 (3.2).
A multi-state model was fitted to the data enabling calculation of the probability of the progression to each stage, as demonstrated by Keown-Stoneman et al. 17 The mstate package in R was used to construct this multi-state model 18 
| RE SULTS
A total of 99 subjects were included in the current study. Of these subjects, 55 were female. At SFBN-NFS study entry, 88 subjects met the criteria for bipolar I disorder and 11 met the criteria for bipolar The inter-rater reliability of assigning stages to the LCM-r, was 0.69 using a Fleiss Kappa, signifying high concordance among three raters. 24 Before the onset of bipolar disorder, eleven subjects (12%) had fulfilled criteria for stage 0, defined by having at least one bipolar parent. Seventy-five subjects (75%) had experienced a period of prodromal symptoms (stage 1)-non-specific psychiatric symptoms or depressive episode(s)-prior to progression through stage 2. In adding covariates to our data, their influence on the transition hazards was calculated (see Table 3 ). The hazard ratio reflects the increase in transition rate for a specified covariate within a group, for example male vs female sex. A biphasic onset for both mania-depression (MD) or depression-mania (DM) increased the progression rate from stage 2 to 3 (HR 2.68 and 3.34) as well as male sex (HR 1.78).
| D ISCUSS I ON
We tested the applicability of a staging model for BD based on episode recurrence as proposed by Berk et al 6 and assessed the Although it remains unclear whether BD must be conceptualized as a neuroprogressive condition, 25 our study has added to the evidence of general illness progression to more advanced stages as recently summarized by Kessing et al. 26 We assessed the influence of covariates on the transition rate, ie the rate at which subjects progressed through the stages. Biphasic over monophasic episodes at the time at onset of BD were the strongest predictor of a faster transition from stage 2 to 3, irrespective of the order of the directionality of the mood episode, ie depressionmania and mania-depression subjects. By definition, subjects with mania followed by depression enter stage 3. Our findings are in line with Turvey et al, 27 finding a positive relation between poor prognosis and poly-phasic first episodes.
Several epidemiological studies reported no difference in the prevalence of BD between sexes (4-6), although one study found women to be at higher risk for recurrence of mood episodes (5).
However, in the first 5 years, our findings indicate a higher transition hazard for stage 2 to 3 for males, underlining the importance of staging models in studies investigating sex differences in BD.
Several studies 28, 29 have shown an increased risk for developing any mood disorder in offspring of bipolar patients. Still, once BD occurred, we found no difference in transition hazard between the groups with and without a parent with BD. Although a relationship between an early age at onset and a poorer prognosis has been widely reported, 22, 23, 30 we found no difference in transition rate for the group with onset ≤ age 18. Transitions from stage 2 to 4 and between stage 3 and 4 were not significantly influenced by any of the tested variables, although the group that transitioned from 2 to 4 was too small to draw any final conclusions.
The main strengths of our study are the unique set of meticulously gathered longitudinal illness course data, at that time collected without any staging model in mind, and the use of current advanced statistical techniques. Since retrospective life chart data were used, dropout during the period under study was no concern.
Our study has several limitations. Our dataset consisted of 99 subjects, resulting in a limited amount of covariates to be tested. One of the core controversies about clinical staging is whether it is meaningful when understanding the underlying pathophysiology is limited and biomarkers are lacking. 34 However, our study shows that application of a staging model based on the clinical course does provide new insights into illness progression thereby providing a valid framework in which the influence of different variables or biomarkers on the illness progression can be investigated.
Although the current study may predict the course of BD on a group level, predictions on a personal level cannot be made yet, clinical profiling being the next step towards a more personalized diagnosis and treatment. For example, in earlier stages, the disorder may respond well to monotherapy, [35] [36] [37] with better compliance and fewer side effects, while later stages may require more complex treatments. Awareness of a staging model could improve interventions during prodromal stages, often called the 'window of opportunity' to minimize or prevent further episodes.
In conclusion, our results suggest that clinical staging is a useful model to describe the progression of BD. Application of a staging model on longitudinal illness course data is possible and informative.
Future studies are recommended, using larger samples enabling the study of sub-stages and other covariates, to further refine the pre- 
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